You searched for "internet"
ST1 Ophthalmology Interview Course 20 Jan 24 (Virtual)
This course is run by current trainees successful in the 2023 application cycle, with multiple members scoring 100% on the interview and ranking in the top 10 nationally. The course is designed to maximise your chances of success. Interview Course•...A unique case of macular burn from ‘toy’ laser
The first laser was created in 1960 and its name is an acronym for ‘light amplification by stimulated emission of radiation’. Laser technology has been used for medical, industrial, research and entertainment purposes in a variety of fields following extensive...Chrome extensions
Chrome is the most popular internet browser, with 44% of the market share (April ‘19). The other browsers of relevance are: Safari (31%) and Firefox (14%). Both Chrome and Firefox can be used on PC and Mac. Safari is only...Useful, interesting, or maybe both
This column is often, but not always, about ophthalmic tech. This is one of those ‘not always’ editions. Time to share some interesting or useful things from the internet which can help in a number of ways, from preparing presentations...What's trending Oct/Nov 2025
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #AlienEarth #TheEye One of the best shows to recently start streaming is, in my opinion, Alien: Earth. The cosmic horror of...Preparing to sit the FRCOphth Part 1 as a new FY1: A modern financial, educational and AI-enhanced study guide
One week into my first year as a doctor, buried under a mountain of ward jobs, night shifts and the sheer vertical learning curve of FY1, I decided to challenge myself further: I booked the FRCOphth Part 1 exam. The...Applying for ophthalmology ST1 in 2026: What’s new?
Competition for ophthalmology ST1 has intensified steadily over recent cycles, rising from ~9:1 (2022) to ~10:1 (2023), ~14:1 (2024) and ~22:1 (2025) [1]. Against this background, applicants benefit from a structured approach: mapping achievements to portfolio domains early, identifying gaps...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
